Expert Perspectives on the Management of SG-Related Neutropenia

Author(s):

This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.

EP: 1.Overview of Current ADCs in Breast Cancer

EP: 2.ADCs in Breast Cancer: Mechanism of Action, and Components

EP: 3.Overview of SG-Related Neutropenia Rates in Real-Life Setting and in Clinical Trials

Now Viewing

EP: 4.Expert Perspectives on the Management of SG-Related Neutropenia

EP: 5.Navigating SG-related Diarrhea

EP: 6.Expert Insights: SG Adverse Events Management including Alopecia & Nausea

EP: 7.Overview of Cardiotoxicity Risk with T-DXd and Monitoring Strategies along with Anti-Nausea strategies

EP: 8.Clinical Management Considerations: Pneumonitis associated with T-DXd

EP: 9.Expert Perspectives: T-DM1 Adverse Events Overview and Management Strategies

EP: 10.Role of Multidisciplinary Team in the Management of Patients Receiving ADCs in Breast Cancer

EP: 11.Future Perspectives on ADCs in Breast Cancer

EP: 12.Expert Insights: Investigational ADCs Safety Profiles

EP: 13.Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

Video content above is prompted by the following:

Please comment on your management strategy to mitigate neutropenia associated with SG.
What patient characteristics do you consider when deciding to utilize prophylactic growth factor support vs. utilize GCSF as secondary prophylaxis in your clinical practice?
What days do you typically administer either pegylated growth factors and/or daily filgrastim?
Please comment on your management strategy to mitigate neutropenia (any similarities vs. differences)